These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21468046)

  • 21. Circulating tumor cells in patients with breast cancer: monitoring chemotherapy success.
    Ušiaková Z; Mikulová V; Pintérová D; Brychta M; Valchář J; Kubecová M; Tesařová P; Bobek V; Kološtová K
    In Vivo; 2014; 28(4):605-14. PubMed ID: 24982230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of circulating tumor cells in the context of treatment: prognostic value in breast cancer.
    Serrano MJ; Sánchez-Rovira P; Delgado-Rodriguez M; Gaforio JJ
    Cancer Biol Ther; 2009 Apr; 8(8):671-5. PubMed ID: 19242121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic Breast Cancer.
    Tan W; Liang G; Xie X; Jiang W; Tan L; Sanders AJ; Liu Z; Ling Y; Zhong W; Tian Z; Lin W; Gong C
    Oncologist; 2019 Nov; 24(11):e1044-e1054. PubMed ID: 31300482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Sparano J; O'Neill A; Alpaugh K; Wolff AC; Northfelt DW; Dang CT; Sledge GW; Miller KD
    JAMA Oncol; 2018 Dec; 4(12):1700-1706. PubMed ID: 30054636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of Survivin-expressing circulating cancer cells in the peripheral blood of breast cancer patients by a RT-PCR ELISA.
    Yie SM; Luo B; Ye NY; Xie K; Ye SR
    Clin Exp Metastasis; 2006; 23(5-6):279-89. PubMed ID: 17086357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive and prognostic value of folate receptor-positive circulating tumor cells in small cell lung cancer patients treated with first-line chemotherapy.
    Shen J; Zhao J; Jiang T; Li X; Zhao C; Su C; Zhou C
    Oncotarget; 2017 Jul; 8(30):49044-49052. PubMed ID: 28467771
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients.
    Wong NS; Kahn HJ; Zhang L; Oldfield S; Yang LY; Marks A; Trudeau ME
    Breast Cancer Res Treat; 2006 Sep; 99(1):63-9. PubMed ID: 16541316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?
    Dawood S; Broglio K; Valero V; Reuben J; Handy B; Islam R; Jackson S; Hortobagyi GN; Fritsche H; Cristofanilli M
    Cancer; 2008 Nov; 113(9):2422-30. PubMed ID: 18785255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer.
    Mego M; Zuo Z; Gao H; Cohen EN; Giordano A; Tin S; Anfossi S; Jackson S; Woodward W; Ueno NT; Valero V; Alvarez RH; Hortobagyi GN; Khoury JD; Cristofanilli M; Reuben JM
    Thromb Haemost; 2015 Mar; 113(3):593-8. PubMed ID: 25373787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
    Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
    BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of circulating tumor cells in breast cancer patients: prognostic predictive role.
    Turker I; Uyeturk U; Sonmez OU; Oksuzoglu B; Helvaci K; Arslan UY; Budakoglu B; Alkis N; Aksoy S; Zengin N
    Asian Pac J Cancer Prev; 2013; 14(3):1601-7. PubMed ID: 23679243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.
    Wallwiener M; Hartkopf AD; Baccelli I; Riethdorf S; Schott S; Pantel K; Marmé F; Sohn C; Trumpp A; Rack B; Aktas B; Solomayer EF; Müller V; Janni W; Schneeweiss A; Fehm TN
    Breast Cancer Res Treat; 2013 Jan; 137(2):503-10. PubMed ID: 23271327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer.
    Deutsch TM; Riethdorf S; Nees J; Hartkopf AD; Schönfisch B; Domschke C; Sprick MR; Schütz F; Brucker SY; Stefanovic S; Sohn C; Pantel K; Trumpp A; Schneeweiss A; Wallwiener M
    Breast Cancer Res Treat; 2016 Nov; 160(2):277-290. PubMed ID: 27696083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial.
    Gennari A; Foca F; Zamarchi R; Rocca A; Amadori D; De Censi A; Bologna A; Cavanna L; Gianni L; Scaltriti L; Rossi E; Facchinetti A; Martini V; Bruzzi P; Nanni O
    Breast Cancer Res Treat; 2020 May; 181(1):61-68. PubMed ID: 32200486
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer.
    Mu Z; Wang C; Ye Z; Rossi G; Sun C; Li L; Zhu Z; Yang H; Cristofanilli M
    Breast Cancer Res Treat; 2017 Oct; 165(3):733-741. PubMed ID: 28687903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies.
    Tewes M; Aktas B; Welt A; Mueller S; Hauch S; Kimmig R; Kasimir-Bauer S
    Breast Cancer Res Treat; 2009 Jun; 115(3):581-90. PubMed ID: 18679793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells.
    Mego M; De Giorgi U; Dawood S; Wang X; Valero V; Andreopoulou E; Handy B; Ueno NT; Reuben JM; Cristofanilli M
    Int J Cancer; 2011 Jul; 129(2):417-23. PubMed ID: 20857493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pretreatment and Posttreatment Evaluations of Circulating Tumor Cells（CTC）in Patients with Metastatic Breast Cancer].
    Okabe M; Toh U; Iwakuma N; Mishima M; Matsueda S; Shichijo S; Itoh K; Akagi Y
    Gan To Kagaku Ryoho; 2015 Oct; 42(10):1237-9. PubMed ID: 26489558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019.
    Paoletti C; Li Y; Muñiz MC; Kidwell KM; Aung K; Thomas DG; Brown ME; Abramson VG; Irvin WJ; Lin NU; Liu MC; Nanda R; Nangia JR; Storniolo AM; Traina TA; Vaklavas C; Van Poznak CH; Wolff AC; Forero-Torres A; Hayes DF;
    Clin Cancer Res; 2015 Jun; 21(12):2771-9. PubMed ID: 25779948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.